Bioequivalence and pharmacokinetic comparison of 3 metformin extended/sustained release tablets in healthy Indian male volunteers

Arzneimittel-Forschung/Drug Research

Volumn 62, Issue 1, 2012, Pages 22-26

  Batolar, L S ^a   Iqbal, M ^c   Monif, T ^b   Khuroo, A ^b   Sharma, P L ^a  

^a HAMDARD UNIVERSITY   (India)

^b Ranbaxy Research Laboratory   (India)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

bioequivalence; extended sustained release; metformin; pharmacokinetics

Indexed keywords

BIGOMET SR; GENERIC DRUG; GLYCOMET SR; METFORMIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CROSSOVER PROCEDURE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG TOLERABILITY; EXTENDED DRUG RELEASE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; OPEN STUDY; RANDOMIZATION; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; MIDDLE AGED; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; TABLET;

ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 84858735644     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1295428     Document Type: Article

References (17)

1. Kirpichnikov D, McFarlane S I, Sowers J R. Metformin: an update. Ann Intern Med: 2002; 137 25 33 (Pubitemid 34705373)
2. Goodarzi M O, Bryer-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab: 2005; 7 654 665 (Pubitemid 41601070)
3. Bailey C J. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab: 2005; 7 675 691 (Pubitemid 41601072)
4. Timmins P, Donahue S, Meeker J et al. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet: 2005; 44 721 729 (Pubitemid 40994081)
5. Prescribing Information Glucophage & Glucophage XR (metformin and metformin extended release tablets). USA Prinston (NJ): Bristol-Myers Squibb Company, January 2009
6. Schwartz S L, Gordi T, Hou E et al. Clinical development of metformin extended-release tablets for type 2 diabetes: an overview. Expert Opin Drug Metab Toxicol: 2008; 4 1235 1243
7. Al Hawari S, AlGaai E, Yusuf A et al. Bioequivalence study of two metformin formulations. Arzneimittelforschung: 2007; 57 192 195 (Pubitemid 46724188)
8. Atanasova I, Bozhinova K, Todorova D et al. Pharmacokinetics and comparative bioavailability of two metformin formulations after single-dose administration in healthy subjects. Clin Drug Investig: 2003; 23 743 749 (Pubitemid 37373796)
9. Najib N, Idkaidek N, Beshtawi M et al. Bioequivalence evaluation of two brands of metformin 500 mg tablets (Dialon & Glucophage) - in healthy human volunteers. Biopharm Drug Dispos: 2002; 23 301 306 (Pubitemid 35203430)
10. Yuen K H, Wong J W, Billa N et al. Bioequivalence of a generic metformin tablet preparation. Int J Clin Pharmacol Ther: 1999; 37 319 322 (Pubitemid 29338487)
11. Li J, Jin Y, Wang T Y et al. Relative bioavailability and bioequivalence of metforphin hydrochloride extended-released and immediate-released tablets in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet: 2007; 32 21 28 (Pubitemid 46649807)
12. US Food and Drug Administration, Guidance for Industry: [Internet] Bioanalytical Method Validation. May2001 (cited on November 13, 2008). Available from www.fda.gov/CDER/GUIDANCE/4252fnl.htm
13. US Food and Drug Administration Guidance for Industry:[Internet]. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, 2003(cited on November 13, 2008) Available from http://www.cdsco.nic.in/html/BE%20Guidelines%20Draft%20Ver10%20March%2016,%2005. pdf
14. Central Drugs Standard Control Organization Guidelines for bioavailability & bioequivalence studies. [Internet]. Ministry of Health and Family Affair, Govt. of India, March, 2005 (cited on November 2008). Available from http://www.cdsco.nic.in/html/BE%20Guidelines%20Draft%20Ver10%20March%2016, %2005.pdf
15. Shu Y, Sheardown S A, Brown C et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest: 2007; 117 1422 1431 (Pubitemid 46718430)
16. Song I S, Shin H J, Shim E J et al. Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin. Clin Pharmacol Ther: 2008; 84 559 562
17. Lalau J D, Lacroix C, Compagnon P et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care: 1995; 18 779 784